Accelerating TIL Manufacturing Turnaround & Improving Safety with the FAST-TIL Platform
Time: 2:30 pm
day: Conference Day One CMC Track PM
Details:
- Presenting a manufacturing platform, achieving 13-19-day turnaround with a closed system to enhance safety and consistency
- Highlighting Phase I clinical results showing strong efficacy and a favorable safety profile, with reduced lymphodepletion and IL-2 dosing
- Exploring how streamlined CMC processes support rapid, scalable, and patient-friendly TIL therapy delivery
